CSL Behring's Kcentra wins FDA nod as antidote to warfarin

The FDA has approved CSL Behring's prothrombin complex concentrate Kcentra as a reversal agent for the anticoagulant warfarin. Health care providers will not need to match Kcentra with a patient's blood type, so it can be used faster than plasma to reverse the effects of warfarin. It cannot be used to reverse the effects of newer anticoagulants dabigatran and rivaroxaban.

View Full Article in:

Los Angeles Times (tiered subscription model) · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care